# Glucophage Immediate Release (GIR) China Bioequivalence Study

> **NCT03393208** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Test GIR
- **DRUG:** Reference GIR

## Key facts

- **NCT ID:** NCT03393208
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-10
- **Primary completion:** 2018-01-29
- **Final completion:** 2018-01-29
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393208, "Glucophage Immediate Release (GIR) China Bioequivalence Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03393208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*